Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-04-24 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于董事会秘书减持计划实施完毕的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a company director/executive (the board secretary). It details the number of shares reduced, the method, dates, and compliance with relevant securities laws. This fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives. The document is short and focused solely on this share reduction event, with no financial statements or broader company performance data. Therefore, it is classified as a Director's Dealing (DIRS).
2019-04-24 Chinese
关于部分董事高管减持股份的预披露公告
Director's Dealing Classification · 100% confidence The document is a pre-disclosure announcement regarding planned share reduction by certain company directors and senior management. It details the names of the directors, the number of shares they intend to reduce, the reasons for reduction, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report attached. The content focuses on insider share transactions by company directors. Therefore, this document fits the category of Director's Dealing (DIRS). The document length is short and it is not an announcement of a report publication or regulatory filing, but a direct disclosure of insider share transactions.
2019-04-23 Chinese
关于使用部分闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of using idle funds for cash management, including details of purchasing financial products, risk management, and impact on the company. It references prior shareholder meeting resolutions and provides detailed financial figures related to cash management activities. The document is not a full financial report like an annual or interim report, nor is it a transcript, audit, or legal proceeding. It is a regulatory announcement about capital management activities, specifically cash management and investment of idle funds. This fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage. The document length is about 5405 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2019-04-23 Chinese
关于部分理财产品到期赎回的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the progress of redemption of certain financial products (理财产品) that have matured. It details specific transactions, investment risks, measures taken, and the impact on the company. It references prior shareholder meeting resolutions and previous announcements but does not contain comprehensive financial statements or detailed financial performance data. The document is focused on updates about capital management activities, specifically the use of idle funds in financial products and their redemption status. It is not a full annual or interim report, nor is it a call transcript or management report. It is an update on financing/capital management activities, fitting the Capital/Financing Update category (CAP). The document length is about 5,081 characters, which is sufficient for a substantive announcement but not a full report. Therefore, the best classification is Capital/Financing Update (CAP).
2019-04-22 Chinese
关于“血液透析联合血液灌流治疗对维持性血透患者生存率影响的多中心、开放、随机、平行对照研究”结果的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the results of a multi-center, randomized clinical trial (RCT) related to one of its medical products. It details the study design, participating institutions, patient numbers, and key findings of the clinical research. The document does not contain financial statements, management discussion, or regulatory certifications. It is not an annual or quarterly report, nor is it a call transcript or governance-related document. The content is focused on clinical trial results and their potential impact on the company, presented as an official announcement to investors and the public. Given the document length (2365 characters) and the nature of the content, it is an announcement of research results rather than a detailed report or financial filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-04-19 Chinese
关于2017年股票期权激励计划首次授予股票期权第一个行权期采用自主行权模式的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement by the company regarding the first exercise period of a 2017 stock option incentive plan, detailing the exercise arrangements, pricing, compliance, and accounting impact. It is a notification about stock option exercise rights and procedures, not a financial report or earnings release. The document length is under 5,000 characters and it does not contain financial statements or detailed financial analysis. It is an announcement related to capital changes (stock option exercise and issuance of shares to option holders). Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2019-04-19 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.